Sergey Ryabichko

Sergey Ryabichko, PhD, currently serves as a Research Scientist at the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry and N.I. Pirogov Russian National Research Medical University, focusing on delivering therapeutic large gene cassettes for the treatment of recessive dystrophic epidermolysis bullosa. Previously, Sergey was a Postdoctoral Research Associate at Princeton University, contributing to the 4D Nucleome project, utilizing advanced techniques to study gene activity and chromatin landscape. Sergey’s earlier experience includes roles as a Junior Researcher at the Institute of Gene Biology, investigating gene transcription regulation, and as a graduate student at Kazan State University, where a PhD in Biochemistry and Microbiology was attained. Sergey co-founded Bioliquid Pro, developing a fungicide, and contributed to the creation of commercial ELISA kits at XEMA. Advanced educational background includes multiple degrees from Kazan State University and visiting scholar positions at institutions like UTHealth Houston and the University of Regensburg.